Aurinia Pharmaceuticals(AUPH),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

AUPH Aurinia Pharmaceuticals

Trading 12-10 10:19:24 EST

15.69

+0.16

+1.03%

High15.73	Low15.50	Vol159.93K
Open15.53	D1 Closing15.53	Amplitude1.48%
Mkt Cap2.07B	Tradable Cap2.01B	Total Shares131.84M
T/O2.50M	T/O Rate0.12%	Tradable Shares128.06M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"AUPH","market":"US","secType":"STK","nameCN":"Aurinia Pharmaceuticals","latestPrice":15.69,"timestamp":1765379957578,"preClose":15.53,"halted":0,"volume":159928,"delay":0,"floatShares":128060726,"shares":131840559,"eps":0.5501,"marketStatus":"Trading","change":0.16,"latestTime":"12-10 10:19:24 EST","open":15.53,"high":15.73,"low":15.5,"amount":2497357.603136,"amplitude":0.01481,"askPrice":15.69,"askSize":96,"bidPrice":15.64,"bidSize":110,"shortable":3,"etf":0,"ttmEps":0.5501,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1765400400000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":951454800000,"exchange":"NASDAQ","adjPreClose":15.53,"preHourTrading":{"tag":"盘前","latestPrice":15.56,"preClose":15.53,"latestTime":"09:25 EST","volume":35401,"amount":550740.968215,"timestamp":1765376700048},"postHourTrading":{"tag":"盘后","latestPrice":15.54,"preClose":15.53,"latestTime":"19:58 EST","volume":95188,"amount":1478610.0415,"timestamp":1765328294477},"volumeRatio":0.729436,"impliedVol":0.5085,"impliedVolPercentile":0.596},"requestUrl":"/m/hq/s/AUPH/tweets","defaultTab":"tweets","newsList":[{"id":"2588202905","title":"Aurinia Pharmaceuticals Shares Fall After Leerink Partners Downgrade","url":"https://stock-news.laohu8.com/highlight/detail?id=2588202905","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588202905?lang=en_us&edition=fundamental","pubTime":"2025-12-04 04:36","pubTimestamp":1764794183,"startTime":"0","endTime":"0","summary":"Aurinia Pharmaceuticals  shares fell 6.6% in recent Wednesday trading after Leerink Partners downgraded the stock to market perform from outperform and increased its price target to $16 from $15.Intraday volume topped 2.22 million shares, versus the daily average of 1.77 million.Price: 14.86, Change: -1.05, Percent Change: -6.60","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["AUPH"],"gpt_icon":0},{"id":"2588041960","title":"Aurinia Pharmaceuticals Cut to Market Perform From Outperform by Leerink Partners","url":"https://stock-news.laohu8.com/highlight/detail?id=2588041960","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588041960?lang=en_us&edition=fundamental","pubTime":"2025-12-03 21:43","pubTimestamp":1764769380,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/AUPH/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 03, 2025 08:43 ET (13:43 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AUPH"],"gpt_icon":0},{"id":"2588868043","title":"Leerink Partners Downgrades Aurinia Pharmaceuticals to Market Perform From Outperform, Adjusts PT to $16 From $15","url":"https://stock-news.laohu8.com/highlight/detail?id=2588868043","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588868043?lang=en_us&edition=fundamental","pubTime":"2025-12-03 19:40","pubTimestamp":1764762041,"startTime":"0","endTime":"0","summary":"Aurinia Pharmaceuticals (AUPH) has an average rating of overweight and mean price target of $16.71, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PT","AUPH"],"gpt_icon":0},{"id":"2588048341","title":"Aurinia Pharmaceuticals Inc : Leerink Partners Cuts to Market Perform From Outperform; Raises Target Price to $16 From $15","url":"https://stock-news.laohu8.com/highlight/detail?id=2588048341","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588048341?lang=en_us&edition=fundamental","pubTime":"2025-12-03 19:14","pubTimestamp":1764760487,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nFWN3X9087:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","AUPH"],"gpt_icon":0},{"id":"2586220603","title":"A Look at Aurinia Pharmaceuticals (NasdaqGM:AUPH) Valuation Following Recent Share Price Gains","url":"https://stock-news.laohu8.com/highlight/detail?id=2586220603","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586220603?lang=en_us&edition=fundamental","pubTime":"2025-11-28 03:22","pubTimestamp":1764271326,"startTime":"0","endTime":"0","summary":"Aurinia Pharmaceuticals (AUPH) shares have been steadily gaining ground this month. This trend reflects investor optimism around the company’s performance in the autoimmune therapeutics space. Recent trading shows a positive momentum for the stock.\nSee our latest analysis for Aurinia Pharmaceuticals.\nAurinia Pharmaceuticals' 1-month share price return of 33.2% is part of an even stronger year-to-date rally, with shares climbing 86.66%. The stock’s 1-year total shareholder return stands at...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-auph/aurinia-pharmaceuticals/news/a-look-at-aurinia-pharmaceuticals-nasdaqgmauph-valuation-fol","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-auph/aurinia-pharmaceuticals/news/a-look-at-aurinia-pharmaceuticals-nasdaqgmauph-valuation-fol","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","AUPH"],"gpt_icon":0},{"id":"2584925998","title":"Aurinia Pharmaceuticals Q3 Operating Income USD 29.745 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2584925998","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584925998?lang=en_us&edition=fundamental","pubTime":"2025-11-20 00:30","pubTimestamp":1763569830,"startTime":"0","endTime":"0","summary":"Nov 04 (Reuters) - Aurinia Pharmaceuticals Q3 product revenue USD 70.627 million.:  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))  Source Date/Time = 04-NOV-202510:55:11.793 GMT","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nRSD2C81Cy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AUPH"],"gpt_icon":0},{"id":"1128418193","title":"Stock Track | Aurinia Pharmaceuticals Soars 5.04% Following Strong Q3 Results and Raised 2025 Guidance","url":"https://stock-news.laohu8.com/highlight/detail?id=1128418193","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1128418193?lang=en_us&edition=fundamental","pubTime":"2025-11-12 03:02","pubTimestamp":1762887765,"startTime":"0","endTime":"0","summary":"Aurinia Pharmaceuticals (AUPH) saw its stock soar 5.04% in intraday trading on Tuesday, following the company's impressive third-quarter results and an optimistic outlook for 2025. The...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["AUPH"],"gpt_icon":0},{"id":"2582360230","title":"Aurinia Pharmaceuticals (NasdaqGM:AUPH): Valuation Insights Following Strong Q3 Results and Raised 2025 Guidance","url":"https://stock-news.laohu8.com/highlight/detail?id=2582360230","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582360230?lang=en_us&edition=fundamental","pubTime":"2025-11-11 22:30","pubTimestamp":1762871436,"startTime":"0","endTime":"0","summary":"Aurinia Pharmaceuticals (AUPH) just delivered a strong show for investors with better-than-expected third quarter results and an updated outlook for 2025. The company raised both its revenue and net product sales guidance, which suggests growing confidence in its business trajectory.\nSee our latest analysis for Aurinia Pharmaceuticals.\nAurinia Pharmaceuticals’ strong financial report and higher guidance have clearly energized the stock, with a 13% seven-day share price return and an...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-auph/aurinia-pharmaceuticals/news/aurinia-pharmaceuticals-nasdaqgmauph-valuation-insights-foll","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-auph/aurinia-pharmaceuticals/news/aurinia-pharmaceuticals-nasdaqgmauph-valuation-insights-foll","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["AUPH","DCF","BK4139"],"gpt_icon":0},{"id":"2581839558","title":"Aurinia Pharmaceuticals Shares Rise After Jefferies Upgrade","url":"https://stock-news.laohu8.com/highlight/detail?id=2581839558","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581839558?lang=en_us&edition=fundamental","pubTime":"2025-11-08 04:17","pubTimestamp":1762546672,"startTime":"0","endTime":"0","summary":"Aurinia Pharmaceuticals  shares were up 4.4% in recent Friday trading after Jefferies upgraded the stock to buy from hold and adjusted its price target to $21 from $10.Trading volume stood at over 1.9 million shares, versus the daily average of about 1.8 million.Price: 14.56, Change: +0.61, Percent Change: +4.37","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["AUPH"],"gpt_icon":0},{"id":"1141642479","title":"Stock Track | Aurinia Pharmaceuticals Soars 9.23% Pre-Market on Jefferies Upgrade and Doubled Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=1141642479","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1141642479?lang=en_us&edition=fundamental","pubTime":"2025-11-07 22:50","pubTimestamp":1762527020,"startTime":"0","endTime":"0","summary":"Shares of Aurinia Pharmaceuticals (AUPH) are soaring 9.23% in pre-market trading on Friday, following a significant upgrade from Jefferies. The investment bank raised its rating on the...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["AUPH"],"gpt_icon":0},{"id":"2581800700","title":"Aurinia Pharmaceuticals Raised to Buy From Hold by Jefferies","url":"https://stock-news.laohu8.com/highlight/detail?id=2581800700","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581800700?lang=en_us&edition=fundamental","pubTime":"2025-11-07 20:21","pubTimestamp":1762518060,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/AUPH/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 07, 2025 07:21 ET (12:21 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AUPH"],"gpt_icon":0},{"id":"2581057420","title":"Aurinia Pharmaceuticals upgraded to Buy from Hold at Jefferies","url":"https://stock-news.laohu8.com/highlight/detail?id=2581057420","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581057420?lang=en_us&edition=fundamental","pubTime":"2025-11-07 18:15","pubTimestamp":1762510539,"startTime":"0","endTime":"0","summary":"Jefferies upgraded Aurinia Pharmaceuticals (AUPH) to Buy from Hold with a price target of $21, up from $10. The company’s commercial performance wi...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/aurinia-pharmaceuticals-upgraded-to-buy-from-hold-at-jefferies-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/aurinia-pharmaceuticals-upgraded-to-buy-from-hold-at-jefferies-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AUPH"],"gpt_icon":0},{"id":"2581092514","title":"Bloom Burton downgrades Aurinia Pharmaceuticals (AUPH) to a Hold","url":"https://stock-news.laohu8.com/highlight/detail?id=2581092514","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581092514?lang=en_us&edition=fundamental","pubTime":"2025-11-06 22:57","pubTimestamp":1762441047,"startTime":"0","endTime":"0","summary":"Bloom Burton analyst David Martin PhD downgraded Aurinia Pharmaceuticals to a Hold yesterday and set a price target of $13.00. According to TipRank...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/bloom-burton-downgrades-aurinia-pharmaceuticals-auph-to-a-hold-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/bloom-burton-downgrades-aurinia-pharmaceuticals-auph-to-a-hold-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AUPH"],"gpt_icon":0},{"id":"1134482445","title":"Stock Track | Aurinia Pharmaceuticals Plummets 5.05% Following RBC Downgrade to Sector Perform","url":"https://stock-news.laohu8.com/highlight/detail?id=1134482445","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1134482445?lang=en_us&edition=fundamental","pubTime":"2025-11-05 23:09","pubTimestamp":1762355352,"startTime":"0","endTime":"0","summary":"Shares of Aurinia Pharmaceuticals (AUPH) plunged 5.05% in pre-market trading on Wednesday following a downgrade by RBC Capital Markets. The Canadian multinational bank revised its rating on the...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["AUPH"],"gpt_icon":0},{"id":"2581727814","title":"Aurinia Pharmaceuticals Cut to Sector Perform From Outperform by RBC Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2581727814","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581727814?lang=en_us&edition=fundamental","pubTime":"2025-11-05 20:46","pubTimestamp":1762346760,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/AUPH/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 05, 2025 07:46 ET (12:46 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AUPH"],"gpt_icon":0},{"id":"2581724604","title":"RBC Downgrades Aurinia Pharmaceuticals to Sector Perform From Outperform, Raises Price Target to $15 From $9, Keeps Speculative Risk","url":"https://stock-news.laohu8.com/highlight/detail?id=2581724604","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581724604?lang=en_us&edition=fundamental","pubTime":"2025-11-05 20:19","pubTimestamp":1762345147,"startTime":"0","endTime":"0","summary":"Aurinia Pharmaceuticals (AUPH) has an average rating of overweight and mean price target of $14.71, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["AUPH"],"gpt_icon":0},{"id":"2581072641","title":"H.C. Wainwright Keeps Their Buy Rating on Aurinia Pharmaceuticals (AUPH)","url":"https://stock-news.laohu8.com/highlight/detail?id=2581072641","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581072641?lang=en_us&edition=fundamental","pubTime":"2025-11-05 19:37","pubTimestamp":1762342641,"startTime":"0","endTime":"0","summary":"In a report released today, Arthur He CFA from H.C. Wainwright maintained a Buy rating on Aurinia Pharmaceuticals, with a price target of $17.00. T...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-keeps-their-buy-rating-on-aurinia-pharmaceuticals-auph-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-keeps-their-buy-rating-on-aurinia-pharmaceuticals-auph-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AUPH"],"gpt_icon":0},{"id":"2581073767","title":"Aurinia Pharmaceuticals (AUPH) was downgraded to a Hold Rating at RBC Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2581073767","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581073767?lang=en_us&edition=fundamental","pubTime":"2025-11-05 05:55","pubTimestamp":1762293320,"startTime":"0","endTime":"0","summary":"In a report released today, Douglas Miehm from RBC Capital downgraded Aurinia Pharmaceuticals to a Hold, with a price target of $15.00. The company...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/aurinia-pharmaceuticals-auph-was-downgraded-to-a-hold-rating-at-rbc-capital-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/aurinia-pharmaceuticals-auph-was-downgraded-to-a-hold-rating-at-rbc-capital-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AUPH"],"gpt_icon":0},{"id":"2581768204","title":"Promising Sales and Market Potential of Lupkynis Drive Buy Rating for Aurinia Pharmaceuticals","url":"https://stock-news.laohu8.com/highlight/detail?id=2581768204","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581768204?lang=en_us&edition=fundamental","pubTime":"2025-11-05 03:05","pubTimestamp":1762283114,"startTime":"0","endTime":"0","summary":"Analyst Stacy Ku of TD Cowen maintained a Buy rating on Aurinia Pharmaceuticals, with a price target of $17.00. Stacy Ku has given her Buy rating d...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/promising-sales-and-market-potential-of-lupkynis-drive-buy-rating-for-aurinia-pharmaceuticals-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/promising-sales-and-market-potential-of-lupkynis-drive-buy-rating-for-aurinia-pharmaceuticals-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AUPH"],"gpt_icon":0},{"id":"2580755988","title":"Aurinia Pharmaceuticals Inc : Leerink Partners Raises Target Price to $15 From $12","url":"https://stock-news.laohu8.com/highlight/detail?id=2580755988","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580755988?lang=en_us&edition=fundamental","pubTime":"2025-11-04 23:12","pubTimestamp":1762269142,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251104:nFWN3WG1IW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AUPH","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.auriniapharma.com","stockEarnings":[{"period":"1week","weight":-0.0239},{"period":"1month","weight":0.063},{"period":"3month","weight":0.2709},{"period":"6month","weight":0.887},{"period":"1year","weight":0.701},{"period":"ytd","weight":0.7294}],"compareEarnings":[{"period":"1week","weight":0.0022},{"period":"1month","weight":0.018},{"period":"3month","weight":0.0473},{"period":"6month","weight":0.1313},{"period":"1year","weight":0.1296},{"period":"ytd","weight":0.1654}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. The company also offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. Aurinia Pharmaceuticals Inc. is headquartered in Victoria, Canada.","yearOnYearQuotes":[{"month":1,"riseRate":0.363636,"avgChangeRate":0.086303},{"month":2,"riseRate":0.454545,"avgChangeRate":0.00852},{"month":3,"riseRate":0.454545,"avgChangeRate":0.093863},{"month":4,"riseRate":0.636364,"avgChangeRate":-0.008728},{"month":5,"riseRate":0.545455,"avgChangeRate":-0.008134},{"month":6,"riseRate":0.454545,"avgChangeRate":-0.02016},{"month":7,"riseRate":0.636364,"avgChangeRate":0.041551},{"month":8,"riseRate":0.545455,"avgChangeRate":-0.014541},{"month":9,"riseRate":0.454545,"avgChangeRate":0.063835},{"month":10,"riseRate":0.583333,"avgChangeRate":0.048963},{"month":11,"riseRate":0.583333,"avgChangeRate":0.036405},{"month":12,"riseRate":0.416667,"avgChangeRate":0.090671}],"exchange":"NASDAQ","name":"Aurinia Pharmaceuticals","nameEN":"Aurinia Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Aurinia Pharmaceuticals(AUPH),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Aurinia Pharmaceuticals(AUPH) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Aurinia Pharmaceuticals,AUPH,Aurinia Pharmaceuticals股票,Aurinia Pharmaceuticals股票老虎,Aurinia Pharmaceuticals股票老虎国际,Aurinia Pharmaceuticals行情,Aurinia Pharmaceuticals股票行情,Aurinia Pharmaceuticals股价,Aurinia Pharmaceuticals股市,Aurinia Pharmaceuticals股票价格,Aurinia Pharmaceuticals股票交易,Aurinia Pharmaceuticals股票购买,Aurinia Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Aurinia Pharmaceuticals(AUPH),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Aurinia Pharmaceuticals(AUPH) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction